Replimune

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3.

CEO

Philip Astley-Sparke

CEOPhilip Astley-Sparke

Employees

206

Employees206

Headquarters

Woburn, Massachusetts

HeadquartersWoburn, Massachusetts

Founded

2015

Founded2015

Employees

206

Employees206

REPL Key Statistics

Market cap

1.29B

Market cap1.29B

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

503.63K

Average volume503.63K

High today

$26.41

High today$26.41

Low today

$25.64

Low today$25.64

Open price

$25.98

Open price$25.98

Volume

354.49K

Volume354.49K

52 Week high

$29.41

52 Week high$29.41

52 Week low

$13.05

52 Week low$13.05

Analyst ratings

100%

of 9 ratings

Buy

100%

Hold

Sell

REPL Earnings

-$0.79

-$0.53

-$0.26

$0.00

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Q1 FY23

Q2 FY23

Q3 FY23

Estimated

-$0.75 per share

Estimated-$0.75 per share

Actual

Expected Feb 10, Pre-Market

ActualExpected Feb 10, Pre-Market

Replimune

Why Robinhood?

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. Show more

REPL Key Statistics

Analyst ratings

100%

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3.